Skip to content

Predictors for Retreatement of OAB After DC Mirabegron

Predictor for Re-treatment of Overactive Bladder Syndrome After Discontinuation of Mirabegron Treatment for Female Overactive Bladder Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04550702
Enrollment
120
Registered
2020-09-16
Start date
2015-01-01
Completion date
2019-07-31
Last updated
2020-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrence of Overactive Bladder Syndrome

Keywords

overactive bladder syndrome, beta-3 agonist, retreatment

Brief summary

Recurrence of female overactive bladder syndrome (OAB) is not uncommon. It is important to decrease the recurrence of female OAB. However, factors predicting recurrence of female OAB, especially for those women who need retreatment is undetermined. Thus, the aim of this study was to elucidate factors predicting retreatment of female OAB.

Detailed description

The medical records, including pad testing, urodynamic studies, lower urinary tract symptoms related questionnaires and bladder diaries of all consecutive women with OAB, who visited urogynecologic clinics in a tertiary referral center, were reviewed. Persistence interval was defined from the date of prescription of mirabegron to the date of discontinuation of mirabegron treatment. Statistical analysis was performed with Kaplan-Meier estimator. Multivariable Cox proportional-hazard model with all variables with p \< 0.25 in the univariate analysis was performed to predict OAB retreatment probability.

Interventions

Mirabegron 25 mg per day

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Women with overactive bladder syndrome * Women complete urodynamic study and bladder diary

Exclusion criteria

* Pregnant women * Incomplete data * Loss of follow-up * Acute or chronic urinary tract infection

Design outcomes

Primary

MeasureTime frameDescription
Recurrent OABJanuary 2015 to July 2019Recurrent OAB with needs to retreatment

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026